Brain cancer drug trial halted after just two patients

NCT ID NCT03149575

Terminated Disease control Sponsor: DelMar Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer that had returned after standard treatments. The trial aimed to see if VAL-083 could help patients live longer. However, the study was stopped early after only 2 people enrolled, so we don't have enough information to know if the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VAL-083 (dianhydrogalactitol)
What this could lead to: If it worked, this could point toward a new treatment option for recurrent glioblastoma patients who have run out of standard therapies.
What could go wrong: The trial was terminated early with only 2 participants enrolled, so no meaningful conclusions can be drawn. It is unclear if VAL-083 is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma glioma susceptibility 1 gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER GBM GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GLIOMA

Contacts and locations

Locations

Atlantic Neuroscience Institute - Brain Tumor Center of NJ

Summit, New Jersey, 07901, United States
Dent Neurosciences Research Center

Amherst, New York, 14226, United States
Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, 90027, United States
Mayo Clinic Cancer Center

Rochester, Minnesota, 55905, United States
University of California, San Francisco - Division of Neuro-Oncology

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.